Modulating effects of bile salt hydrophobicity on bile secretion of the major protein of the bile lipoprotein complex.
Bile lipids are secreted in association with a newly identified major apoprotein called anionic polypeptide fraction-calcium binding protein (APF-CBP), which is synthesized in the hepatocytes and has been detected in both bile and plasma and characterized. The secretion of the lipids in bile depends both on the concentration and the hydrophobicity of the bile salts (BS) secreted. The present study was undertaken to determine whether the synthesis and the secretion of APF-CBP are similarly regulated by BS, using two methods. The synthesis and secretion of labelled, newly synthesized APF-CBP by isolated rat hepatocytes were monitored by solid-phase immunoassay. For this purpose, hepatocytes were incubated with either glycodeoxycholate (GDC) or taurocholate (TC). The synthesis and secretion of labelled, newly synthesized APF-CBP by perfused rat liver were measured by immunological enzyme-linked assay (ELISA) upon perfusing the liver with either GDC or TC. We found that (i) the synthesis and the secretion of APF-CBP were increased during either TC or GDC perfusion, but the increase was more pronounced with TC; (ii) in GDC perfusion the APF-CBP levels measured were more closely related to the levels of bile salts and not to phospholipid levels, (iii) when the two bile salts were perfused in reverse order, i.e., first GDC and then TC, the secretion of APF-CBP in bile decreased when GDC was perfused, but increased when TC was perfused. Similar results were obtained in experiments with isolated hepatocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
Domingo
N
N
INSERM Unité 130, Marseille, France.
Chanussot
F
F
Botta
D
D
Reynier
M O
MO
Crotte
C
C
Hauton
J
J
Lafont
H
H
D000818:Animals; D001059:Apoproteins / Q000096:biosynthesis* / Q000187:drug effects; D001646:Bile / Q000187:drug effects / Q000378:metabolism*; D001647:Bile Acids and Salts / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000096:biosynthesis* / Q000187:drug effects; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D006002:Glycodeoxycholic Acid / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007700:Kinetics; D007930:Leucine / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D013656:Taurocholic Acid / Q000494:pharmacology; D013997:Time Factors
D001059:Apoproteins; D001647:Bile Acids and Salts; D002135:Calcium-Binding Proteins; D007328:Insulin; D008074:Lipoproteins; C076065:anionic polypeptide fraction, rat; D006002:Glycodeoxycholic Acid; D013656:Taurocholic Acid; D007930:Leucine